Challenges in anticancer drug R&D in China

Affiliations

¹ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
² Covance, Shanghai, China.
³ Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Haidian, Beijing, 100142, China.
⁴ Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁵ Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
⁶ National Center for Drug Evaluation, China Food and Drug Administration, Beijing, China.
⁷ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. Electronic address: zhangli6@mail.sysu.edu.cn.

PMID: 30723039
DOI: 10.1016/S1470-2045(18)30865-9

Challenges in anticancer drug R&D in China

Shen Zhao et al. Lancet Oncol. 2019 Feb.

. 2019 Feb;20(2):183-186.

doi: 10.1016/S1470-2045(18)30865-9.

Authors

Affiliations

¹ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
² Covance, Shanghai, China.
³ Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Haidian, Beijing, 100142, China.
⁴ Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁵ Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
⁶ National Center for Drug Evaluation, China Food and Drug Administration, Beijing, China.
⁷ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. Electronic address: zhangli6@mail.sysu.edu.cn.

PMID: 30723039
DOI: 10.1016/S1470-2045(18)30865-9

No abstract available

PubMed Disclaimer

Cited by

Anticancer drug R&D landscape in China.
Zhao S, Zhao H, Lv C, Gong J, Zhang J, Fang W, Li J, Hu X, Ba Y, Xu B, Zhang Y, Fan Y, Li K, Chen X, Yang Z, Shen L, Zhang L. Zhao S, et al. J Hematol Oncol. 2020 May 13;13(1):51. doi: 10.1186/s13045-020-00877-3. J Hematol Oncol. 2020. PMID: 32404176 Free PMC article. No abstract available.
Growing research and development of targeted anticancer drugs in China.
Huang H, Du J, Meng X, Wu D, Yu Y, Wang S, Wang L, Wang W, Tang Y, Li N. Huang H, et al. J Natl Cancer Cent. 2023 Apr 19;3(2):129-134. doi: 10.1016/j.jncc.2023.02.004. eCollection 2023 Jun. J Natl Cancer Cent. 2023. PMID: 39035724 Free PMC article.
Factors influencing willingness to participate in ophthalmic clinical trials and strategies for effective recruitment.
Liang JE, Liang MY, Zhang EE, Peng YY, Chen LL, Deng JY, Lin T, Fu J, Zhang JN, Li SL, Li F, Xiao HM, Huang WM, Liu YH. Liang JE, et al. Int J Ophthalmol. 2024 Jan 18;17(1):157-163. doi: 10.18240/ijo.2024.01.21. eCollection 2024. Int J Ophthalmol. 2024. PMID: 38239943 Free PMC article.
Evolving landscape and academic attitudes toward the controversies of global immuno-oncology trials.
Xu C, Zhang S, Zhang Y, Tang SQ, Fang XL, Zhu GL, Peng L, Liu JQ, Mao YP, Tang LL, Liu Q, Lin AH, Sun Y, Ma J. Xu C, et al. Int J Cancer. 2021 Jul 1;149(1):108-118. doi: 10.1002/ijc.33503. Epub 2021 Feb 22. Int J Cancer. 2021. PMID: 33544890 Free PMC article.
From past to present: tracing the trends of diabetes drug trials in mainland China.
Ma Z, Zhao X, Lin Y, Zhang H, Wu L, Tao Y, Shi H, Li S. Ma Z, et al. Front Endocrinol (Lausanne). 2025 Jan 10;15:1427148. doi: 10.3389/fendo.2024.1427148. eCollection 2024. Front Endocrinol (Lausanne). 2025. PMID: 39866740 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Challenges in anticancer drug R&D in China

Affiliations

Challenges in anticancer drug R&D in China

Authors

Affiliations

Similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources

Full Text Sources